Atrial natriuretic peptide protects against Staphylococcus aureus-induced lung injury and endothelial barrier dysfunction

• Published in: Journal of applied physiology (1985) Vol. 110; no. 1; pp. 213 - 224
• Main Authors: JUNJIE XING, MOLDOBAEVA, Nurgul, BIRUKOVA, Anna A
• Format: Journal Article
• Language: English
• Published: Bethesda, MD American Physiological Society 01.01.2011
• Subjects: Acute Lung Injury - microbiology; Acute Lung Injury - physiopathology; Acute Lung Injury - prevention & control; Animals; Atrial Natriuretic Factor - administration & dosage; Biological and medical sciences; Cells; Dose-Response Relationship, Drug; Endothelium, Vascular - drug effects; Endothelium, Vascular - physiopathology; Fundamental and applied biological sciences. Psychology; Humans; In Vitro Techniques; Inflammatory diseases; Lung diseases; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Morphology; Peptides; Physiology; Proteins; Staphylococcal Infections - microbiology; Staphylococcal Infections - physiopathology; Staphylococcal Infections - prevention & control; Staphylococcus; Staphylococcus infections; Treatment Outcome; Lung disease; Respiratory disease; Lung; pulmonary endothelium; Barrier; Inflammation; Atrial natriuretic peptide; Respiratory system; Endothelium; Vertebrata; Natriuretic hormone; Mammalia; vascular leak; Endothelial dysfunction; Cytoskeleton
• ISSN: 8750-7587; 1522-1601; 1522-1601
• DOI: 10.1152/japplphysiol.00284.2010

Lung inflammation and alterations in endothelial cell (EC) permeability are key events to development of acute lung injury (ALI). Protective effects of atrial natriuretic peptide (ANP) have been shown against inflammatory signaling and endothelial barrier dysfunction induced by gram-negative bacterial wall liposaccharide. We hypothesized that ANP may possess more general protective effects and attenuate lung inflammation and EC barrier dysfunction by suppressing inflammatory cascades and barrier-disruptive mechanisms shared by gram-negative and gram-positive pathogens. C57BL/6J wild-type or ANP knockout mice (Nppa-/-) were treated with gram-positive bacterial cell wall compounds, Staphylococcus aureus-derived peptidoglycan (PepG) and/or lipoteichoic acid (LTA) (intratracheal, 2.5 mg/kg each), with or without ANP (intravenous, 2 μg/kg). In vitro, human pulmonary EC barrier properties were assessed by morphological analysis of gap formation and measurements of transendothelial electrical resistance. LTA and PepG markedly increased pulmonary EC permeability and activated p38 and ERK1/2 MAP kinases, NF-κB, and Rho/Rho kinase signaling. EC barrier dysfunction was further elevated upon combined LTA and PepG treatment, but abolished by ANP pretreatment. In vivo, LTA and PepG-induced accumulation of protein and cells in the bronchoalveolar lavage fluid, tissue neutrophil infiltration, and increased Evans blue extravasation in the lungs was significantly attenuated by intravenous injection of ANP. Accumulation of bronchoalveolar lavage markers of LTA/PepG-induced lung inflammation and barrier dysfunction was further augmented in ANP-/- mice and attenuated by exogenous ANP injection. These results strongly suggest a protective role of ANP in the in vitro and in vivo models of ALI associated with gram-positive infection. Thus ANP may have important implications in therapeutic strategies aimed at the treatment of sepsis and ALI-induced gram-positive bacterial pathogens.